AMLX - NASDAQ
Amylyx Pharmaceuticals, Inc.
$14.31
+7.7%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live Snapshotamlx
Cash and Short Term Investments
Last Annual Value
316.98M
3-Year CAGR
-3%
5-Year CAGR
90%
10-Year CAGR
59%
Amylyx Pharmaceuticals, Inc. Competitors Analysis of Cash and Short Term Investments
| Company | Cash and Short Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | 316.98M | -5.1% | 27.0% | N/A | |
 Relay Therapeutics, Inc. NASDAQ:RLAY | 554.52M | -9.6% | -10.4% | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 245.75M | -6.8% | -19.7% | -4.5% | |
 Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 394.07M | -12.0% | -2.5% | 14.1% | |
 Precigen, Inc. NASDAQ:PGEN | 97.86M | 15.9% | -2.1% | -8.5% | |
 Atai Beckley Inc. NASDAQ:ATAI | 256.04M | 12.6% | -6.7% | N/A | |
 Inhibrx Biosciences, Inc. NASDAQ:INBX | 124.22M | -23.5% | -1.1% | 20.0% | |
 Sana Biotechnology, Inc. NASDAQ:SANA | 138.38M | -12.3% | -24.1% | N/A | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 281.49M | 10.6% | 3.5% | N/A |
Amylyx Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your AMLX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.